N-((1R,3S)-3-((2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-yl)amino)cyclohexyl)-2-morpholinoacetamide

ID: ALA3317985

Chembl Id: CHEMBL3317985

PubChem CID: 118708557

Max Phase: Preclinical

Molecular Formula: C23H27ClFN7O2

Molecular Weight: 487.97

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  O=C(CN1CCOCC1)N[C@@H]1CCC[C@H](Nc2nc(-c3c[nH]c4ncc(Cl)cc34)ncc2F)C1

Standard InChI:  InChI=1S/C23H27ClFN7O2/c24-14-8-17-18(11-27-21(17)26-10-14)22-28-12-19(25)23(31-22)30-16-3-1-2-15(9-16)29-20(33)13-32-4-6-34-7-5-32/h8,10-12,15-16H,1-7,9,13H2,(H,26,27)(H,29,33)(H,28,30,31)/t15-,16+/m1/s1

Standard InChI Key:  BCFLFRBCKLTLPY-CVEARBPZSA-N

Alternative Forms

  1. Parent:

    ALA3317985

    ---

Associated Targets(non-human)

Influenza A virus (11224 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PB2 Polymerase basic protein 2 (86 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 487.97Molecular Weight (Monoisotopic): 487.1899AlogP: 2.98#Rotatable Bonds: 6
Polar Surface Area: 108.06Molecular Species: NEUTRALHBA: 7HBD: 3
#RO5 Violations: HBA (Lipinski): 9HBD (Lipinski): 3#RO5 Violations (Lipinski):
CX Acidic pKa: 12.66CX Basic pKa: 5.49CX LogP: 2.20CX LogD: 2.19
Aromatic Rings: 3Heavy Atoms: 34QED Weighted: 0.49Np Likeness Score: -1.66

References

1. Clark MP, Ledeboer MW, Davies I, Byrn RA, Jones SM, Perola E, Tsai A, Jacobs M, Nti-Addae K, Bandarage UK, Boyd MJ, Bethiel RS, Court JJ, Deng H, Duffy JP, Dorsch WA, Farmer LJ, Gao H, Gu W, Jackson K, Jacobs DH, Kennedy JM, Ledford B, Liang J, Maltais F, Murcko M, Wang T, Wannamaker MW, Bennett HB, Leeman JR, McNeil C, Taylor WP, Memmott C, Jiang M, Rijnbrand R, Bral C, Germann U, Nezami A, Zhang Y, Salituro FG, Bennani YL, Charifson PS..  (2014)  Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2.,  57  (15): [PMID:25019388] [10.1021/jm5007275]

Source